Loading...
Loading...
Deutsche Bank maintains its Hold rating and $14 price target on Amylin Pharmaceuticals
AMLN as takeout offer from Bristol Myers Squibb develops.
Deutsche Bank comments, "Based on weekly IMS TRx, we see following trends: 1) GLP-1 market continues to grow, 2) Bydureon taking share from Byetta, not Victoza & 3) Bydureon growing but behind Victoza launch pace. …We note AMLN shares are trading well above our TP of $14 due to an unconfirmed takeout bid from Bristol Myers Squibb of $22 (Source: Bloomberg Finance LP). We are maintaining Hold rating given the deal is
still unconfirmed and shares can pull back if bidder leaves the table."
AMLN closed at $27.96 on Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in